Leinco Technologies

Anti-Mouse CD134 (Clone OX-86) - APC

Product Code:
 
LEI-C866
Product Group:
 
Primary Antibodies
Host Type:
 
Rat
Antibody Isotype:
 
IgG1 κ
Antibody Clonality:
 
Monoclonal
Antibody Clone:
 
OX-86
Regulatory Status:
 
RUO
Target Species:
 
Mouse
Application:
 
Flow Cytometry
Shipping:
 
2-8°C
Storage:
 
This Allophyc°Cyanin (APC) conjugate is stable when stored at 2-8°C. Do not freeze.
 

No additional charges, what you see is what you pay! *

CodeSizePrice
LEI-C866-50ug50 ug£255.00
Quantity:
LEI-C866-100ug100 ug£295.00
Quantity:
Prices exclude any Taxes / VAT
How to order with us   Contact us
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: US.
Typical lead time: 14-21 working days.
Contact us for more accurate information.
  • Further Information
  • References
  • Related Products
  • Show All

Further Information

Antigen Distribution:
CD134 is expressed on activated CD4 and CD8 T cells, activated regulatory T cells, B cells, NKT cells, NK cells, and neutrophils.
Concentration:
0.2 mg/ml
Conjugate/Tag/Label:
Allophycocyanin (APC)
Format:
This Allophycocyanin (APC) conjugate is formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.4, 1% BSA and 0.09% sodium azide as a preservative.
Formulation:
This Allophycocyanin (APC) conjugate is formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.4, 1% BSA and 0.09% sodium azide as a preservative.
Long Description:
CD134 functions as an important immune checkpoint, and its depletion in murine mouse models demonstrate that lack of CD134 expression leads to reduced CD4+ and CD8+ T cells1. When CD134 is bound by its corresponding ligand (OX-40L), an optimal T cell response is generated and plays a significant role in determining the amount of memory T-cells remaining after the immune response1. CD134 has also been found to play an important role in carcinogenesis, as treatment with activating in vivo antibodies against CD134 enhanced tumor growth, suggesting that CD134 is an important tumor suppressor, and its absence disrupts the immune response to tumors2,3.
Target:
CD134

References

1. Redmond WL, Ruby CE, Weinberg AD. Crit Rev Immunol. 29(3):187-201. 2019 2. Morris A, Vetto JT, Ramstad T, et. al. Breast Cancer Res Treat. 67: 71?80. 2001. 3. Weinberg AD, Rivera MM, Prell R, et. al. J Immunol. 164: 2160?9. 2000. 4. al-Shamkhani A, Birkeland ML, Puklavec M, et. al. Eur J Immunol. Aug;26(8):1695-9. 1996. 5. Higgins LM, McDonald SA, Whittle N, et. al. J Immunol. Jan 1;162(1):486-93. 1999.